Highlights Gabather AB

Equities

GABA

SE0010869552

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 25/06/2024 pm IST			5-day change	1st Jan Change
1.545 ^SEK	-0.96%		-3.44%	+9.57%

30/05	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05	CI
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	10/04	CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	18/03	MT
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	18/03	CI
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	07/03	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	14/12	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/11	CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12/23/12	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	13/23/13	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	08/23/08	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/22/03	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	31/22/31	CI
Gabather Secures Notice Of Allowance For US Patent Claims Covering Neuropsychiatric Drug Synthesis	07/22/07	MT
Gabather Receives Approval to Start the EEG/fMRI Target Engagement Study with the Drug Candidate GT-002	17/22/17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Gabather AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
Gabather AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	17/22/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gabather AB

Equities

GABA

SE0010869552

Highlights

Filters